Changeflow GovPing Healthcare & Life Sciences MindSet Pharma Indole Derivative Serotonergic P...
Routine Notice Added Final

MindSet Pharma Indole Derivative Serotonergic Patent Granted

Favicon for changeflow.com USPTO Patent Grants - Organic Chemistry (C07D)
Published
Detected
Email

Summary

USPTO granted patent US12606543B2 to MindSet Pharma Inc. on April 21, 2026. The patent covers indole derivatives as serotonergic agents useful for activation of serotonin receptors in cells and treating diseases, disorders, or conditions including psychosis, mental illnesses, and CNS disorders.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

USPTO granted patent US12606543B2 to MindSet Pharma Inc. covering indole derivatives of general Formula (I) useful as serotonergic agents. The patent protects compositions including indole derivatives and their use in activation of serotonin receptors for treating diseases, disorders, or conditions including psychosis, mental illnesses and CNS disorders.

Pharmaceutical companies developing serotonergic compounds should review this patent for freedom-to-operate considerations. The 26 granted claims cover compositions, methods of preparation, and therapeutic uses for CNS disorders.

Archived snapshot

Apr 21, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto

Grant US12606543B2 Kind: B2 Apr 21, 2026

Assignee

MINDSET PHARMA INC.

Inventors

Abdelmalik Slassi

Abstract

The present disclosure relates to indole derivatives of general Formula (I), to processes for their preparation, to compositions including indole derivatives of general Formula (I), and to their use in activation of a serotonin receptors in a cell, as well as to treating diseases, disorders, or conditions by activation of a serotonin receptors in a cell. The diseases, disorders, or conditions include, for example, psychosis, mental illnesses and CNS disorders.

CPC Classifications

C07D 403/06 C07D 405/14 C07D 409/14 A61K 31/404 A61K 31/4439

Filing Date

2025-04-25

Application No.

19189862

Claims

26

View original document →

Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 21st, 2026
Instrument
Notice
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12606543B2

Who this affects

Applies to
Pharmaceutical companies Manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent granting IP registration
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!